FREMONT, Calif., April 15, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc. (NASDAQ: RGLS), a leading company developing microRNA therapeutics.
"I am pleased to welcome Dr. Xanthopoulos as our independent board member," said Vikram Lamba, Chief Executive Officer of Zosano Pharma. "He is a veteran life sciences industry CEO whose extensive healthcare, execution and IPO experience will provide Zosano with valuable insight as we pursue potential public options for financing our extensive clinical development program."
Prior to joining Regulus in 2007, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. He co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, and remained a Director until its acquisition by Roche. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals), and participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the Board of Directors of the Biotechnology Industry Organization (BIO), Apricus Biosciences, Sente Inc., and a member of the board of BIOCOM, Southern California's life science industry association.
"I am delighted to join the Zosano Board," said Dr. Xanthopoulos. "Zosano's ZP Patch Technology has the potential to provide novel drug delivery solutions for many therapeutic indications – and I look forward to working with the other Board members and management team to shape the company's future."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts